ImmuPharma Reports Interim Loss Amid P140 Breakthroughs and Partner Talks
ImmuPharma reports £1.8m interim loss amid major P140 breakthroughs (non-immunosuppressive mechanism proven) and active global partner talks.
This article covers information on Immupharma PLC.
LON:IMMThe Bottom Line: Cash Burn vs Clinical Promise
Right, let’s cut through the noise. ImmuPharma’s H1 2025 results show a £1.8 million loss – significantly wider than last year’s £0.4 million. But before you hit the panic button, remember this is biotech: financials only tell half the story. The real meat? Their autoimmune drug candidate P140 just racked up major scientific validation.
Where the Money Went
- R&D spend up 40% to £0.7 million (focused squarely on P140 development)
- £0.7 million loss on derivative revaluations (financial engineering, not core ops)
- Cash reserves fell to £0.4 million (June 2024: £1.1 million)
That cash position looks tight, granted. But crucially, they raised £2.91 million in February 2025 – after this reporting period. That lifeline extends their runway considerably.
P140: The Science Heating Up
Forget dry financials for a moment. The fireworks are in the labs. ImmuPharma dropped two major updates on P140:
January 2025: Diagnostic & Monitoring Breakthrough
New preclinical data suggests P140 could enable earlier autoimmune disease detection and precisely identify which patients will respond best to treatment. This isn’t just about therapy – it’s about smarter, targeted deployment of therapy. Huge for commercial potential.
March 2025: Mechanism of Action Confirmed
For the first time, ImmuPharma proved key hypotheses about how P140 works:
- Unique Mechanism of Action (MOA): It doesn’t just suppress the immune system blindly like many existing drugs.
- Non-immunosuppressive: A major safety advantage – patients aren’t left vulnerable to infections.
- Effective & Safe: Demonstrated across multiple preclinical disease models.
This is the holy grail for autoimmune treatments: restoring immune balance (homeostasis) without crippling the body’s defences. CEO Tim McCarthy isn’t shy about calling this a potential “new standard of care.”
Beyond Lupus: The Expanding Universe of P140
While Systemic Lupus Erythematosus (SLE) remains the flagship target, the implications are broader. P140 has shown compelling activity in:
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Could replace gruelling, costly hospital IV treatments with simple twice-monthly self-injections.
- Asthma (acute/chronic), Gout, Periodontitis, Inflammatory Bowel Disease (IBD): All share the same underlying immune dysfunction P140 targets. Markets crying out for innovation.
This broad applicability massively boosts the platform’s commercial appeal.
Partner Talks & The Road Ahead
This scientific momentum isn’t happening in a vacuum. The RNS explicitly states:
“…active discussions continue with potential global commercial partners.”
This is the critical near-term catalyst. Why now?
- The new MOA data de-risks the technology significantly for partners.
- The diagnostic insights create potential for companion tests – extra revenue streams.
- Patent fortification is underway, strengthening their hand in negotiations.
McCarthy’s priorities are clear: Advance P140 for SLE and CIDP towards market and land those deals. The February fundraise buys them time to negotiate from strength.
Investor Lens: Balancing Risk & Runway
Let’s be clear-eyed:
- The Cash Burn: Continues. Further funding will likely be needed down the line, though partnerships could drastically reduce this burden.
- The Catalyst: A major partnership deal is the single biggest near-term value driver. Progress here trumps quarterly losses.
- The Valuation Case: Rests entirely on P140’s potential. The recent scientific validation is material. It transforms P140 from a hopeful punt into a drug with a proven, differentiated, and safe biological effect.
ImmuPharma remains high-risk, high-reward. But H1 2025 wasn’t just about a bigger loss – it delivered the kind of scientific evidence that makes big pharma partners pick up the phone. Watch the deal flow, not just the cash flow.
Related
Keep reading
Investing
Victrex Upgrades FY26 Profit Guidance as Q4 Momentum Builds
Victrex now expects FY26 underlying profit before tax of £45 million to £47 million after stronger fourth-quarter trading.
JoshuaSeptember 9, 2026
Investing
Cambridge Nutritional Sciences revenue falls 16% as losses widen
CNSL revenue fell 16.3% to £7.0 million, while the company moved into an adjusted EBITDA loss and ended the year with £2.6 million in cash.
JoshuaSeptember 8, 2026
Investing
Manolete Partners trading stays positive as forward book grows
Manolete says FY27 trading remains in line with expectations as realised revenues rise and its portfolio of future cases continues to grow.
JoshuaSeptember 8, 2026
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.